Novavax shares sank as much as 25% after the COVID-19 vaccine maker warned it has"substantial doubt" about its ability to stay in business through next year and it plans cuts to its spending.
The biotech said that while its cash-flow forecast showed it has enough capital to fund its operations, that forecast was subject to"significant uncertainty" around its 2023 revenue, US government funding and unresolved arbitration proceedings with the global vaccine alliance Gavi.
Switzerland Neuesten Nachrichten, Switzerland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Herkunft: Forbes - 🏆 394. / 53 Weiterlesen »